Synchron, Inc. Overview
Pro stress-test →Synchron, Inc. develops neurotechnology and medical devices focused on brain-computer interfaces, commercializing and scaling implantable BCI technology and conducting clinical research and trials for patients with paralysis. The company offers a motor neuroprosthesis called the Stentrode which helps paralyzed patients regain the ability to communicate.
Strategic Profile
Pro stress-test →Synchron has raised $340M from 48 investors including 3cap, Armyn Capital, Axial Partners, and In-Q-Tel. The company completed a Series D funding round in November 2025 with participation from 12 investors. Apple is working with Synchron to develop devices including iPhones that could be controlled using brain implants and users' thoughts.
Competitive Landscape
Pro stress-test →Synchron faces competition from Precision Neuroscience, Neurable, Neuralink, Blackrock Neurotech, and Paradromics. Synchron differentiates through minimally-invasive catheter-based delivery and commercial-stage clinical programs, positioning it between early-stage research companies and Neuralink's more invasive surgical approach.
Industry Context
Synchron, Inc. operates in Neurotechnology / Brain-Computer Interfaces.
Key facts
Founded: 2016 · Headquarters: Brooklyn, US · Employees: 127